Press "esc" to clear
Go to Advanced Search

Showing results

110 of 753
Embargo will expire:
22-Oct-2018 11:00 AM EDT
Released to reporters:
21-Oct-2018 11:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 22-Oct-2018 11:00 AM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Rezvani_K2.jpg
  • Embargo expired:
    10-Oct-2018 5:00 PM EDT

Article ID: 701795

Cancer Patients with Rare Deadly Brain Infection Treated Successfully with Off-the-Shelf Adoptive T-Cell Therapy in Clinical Trial

University of Texas M. D. Anderson Cancer Center

An emerging treatment known as adoptive T-cell therapy has proven effective in a Phase II clinical trial for treating progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection sometimes observed in patients with cancer and other diseases in which the immune system is compromised. The study, led by Katy Rezvani, M.D., Ph.D., professor, Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center, showed marked improvement in three PML patients infused with donor T cells targeting the BK virus. Findings were published in the Oct. 11 online issue of the New England Journal of Medicine.

Released:
9-Oct-2018 5:00 PM EDT
  • Embargo expired:
    8-Oct-2018 11:00 AM EDT

Article ID: 701762

Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage 3 Melanoma

University of Texas M. D. Anderson Cancer Center

The phase II study was led by researchers at The University of Texas MD Anderson Cancer Center. Results of the study, the first randomized neoadjuvant clinical trial of immune checkpoint blockade for melanoma patients, are reported in Nature Medicine.

Released:
7-Oct-2018 4:05 PM EDT
  • Embargo expired:
    4-Oct-2018 7:00 AM EDT

Article ID: 701595

MD Anderson and Cyclacel Pharmaceuticals Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies

University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

Released:
3-Oct-2018 3:50 PM EDT
1538386890391.jpg

Article ID: 701510

MD Anderson Immunologist Jim Allison Awarded Nobel Prize

University of Texas M. D. Anderson Cancer Center

T cell discoveries led to game-changing treatment revolutionizing cancer care

Released:
2-Oct-2018 4:15 PM EDT
HamiltonJaneweb.jpg

Article ID: 701402

New integrated, outpatient program created to combat mental illness, homelessness

University of Texas Health Science Center at Houston

To help break the cycle of mental illness, addiction and homelessness, The University of Texas Health Science Center at Houston (UTHealth) has launched a new integrated, trauma-informed behavioral health program for treatment and recovery support.

Released:
1-Oct-2018 2:05 PM EDT
100661_Glisson_B.jpg
  • Embargo expired:
    27-Sep-2018 11:00 AM EDT

Article ID: 701187

Vaccine, Anti-PD1 Drug Show Promise Against Incurable HPV-Related Cancers

University of Texas M. D. Anderson Cancer Center

A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology.

Released:
26-Sep-2018 4:55 PM EDT
Yi_Qing3x4.jpg

Article ID: 701142

Houston Methodist Adds Depth to Cancer Biology, Surgical Oncology, and Cancer Prevention and Control Programs

Houston Methodist

Houston Methodist Cancer Center has expanded its basic cancer research program, cancer prevention and control efforts, and surgical oncology services with the addition of two national recruits.

Released:
27-Sep-2018 9:00 AM EDT
Eric-Boerwinkle-lab-CreditNashBaker.jpg

Article ID: 701176

UTHealth part of NIH-funded genome center to accelerate precision medicine discoveries

University of Texas Health Science Center at Houston

The University of Texas Health Science Center at Houston (UTHealth) will be part of a new genome center, one of just three created nationally with $28.6 million in funding from the All of Us Research Program of the National Institutes of Health (NIH).

Released:
26-Sep-2018 2:05 PM EDT
152884_Heymach_J1.jpg

Article ID: 701027

Poziotinib Maintains High Response Rate Against Harmful Lung Cancer Mutation

University of Texas M. D. Anderson Cancer Center

A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide unprecedented response rates among stage 4 non-small cell lung cancer patients with genetic mutations that have previously defied treatment.

Released:
24-Sep-2018 4:05 PM EDT

Showing results

110 of 753

Chat now!